SCHEMBL5499205

SCHEMBL5499205

O=C(O)c1ccccc1Oc1cccc(-c2cnc(N(Cc3ccc(C(F)(F)P(=O)(O)O)c(Br)c3)c3ccc(Cl)c(Cl)c3)o2)c1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 8/20 0.36
PTPN2 P17706 4/20 0.36
PLG P00747 4/20 0.33
PLAU P00749 4/20 0.33
PTPN5 P54829 2/20 0.32
PTPRC P08575 1/20 0.31
VDR P11473 1/20 0.31
PLAT P00750 2/20 0.31
F3 P13726 1/20 0.31
CYP1A2 P05177 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2D6 P10635 1/20 0.30
CYP2C9 P11712 1/20 0.30
CYP2C19 P33261 1/20 0.30
CCR2 P41597 1/20 0.30
CCR4 P51679 1/20 0.30
CCR5 P51681 1/20 0.30
NR1H2 P55055 1/20 0.30
NR1H3 Q13133 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5502946 0.93 PTPN1 (0.35) PTPN1PTPN2PTPN5VDRNR1H2
SCHEMBL5514053 0.89 NR1H2 (0.34) PTPN1PTPN2VDRNR1H2NR1H3
SCHEMBL5499218 0.88 PTPN1 (0.37) PTPN1PTPN2PTPN5PTPRC
SCHEMBL5500025 0.86 PTPN1 (0.40) PTPN1PTPN2PTPN5PTPRC
SCHEMBL5503912 0.86 PTPN1 (0.38) PTPN1PTPN2PTPN5
SCHEMBL5499206 0.86 PLG (0.33) PLGPLAUVDRPLATCYP1A2
SCHEMBL5502905 0.86 PTPN1 (0.39) PTPN1PTPN2PTPN5PTPRC
SCHEMBL5499130 0.85 VDR (0.33) VDRCYP1A2NR1H2NR1H3
SCHEMBL5500738 0.84 PTPN1 (0.41) PTPN1PTPN2PTPN5
SCHEMBL5499814 0.84 PTPN1 (0.39) PTPN1PTPN2PTPN5PTPRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1786421-A2 OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES Cengent Therapeutics, Inc. (US) 2007-05-23 EP claimed
US-20060135483-A1 Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases METABASIS THERAPEUTICS, INC. 2006-06-22 US claimed
WO-2006017124-A2 OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES CENGENT THERAPEUTICS, INC. (US) 2006-02-16 WO claimed
EP-1786421-A2 OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES Cengent Therapeutics, Inc. (US) 2007-05-23 EP disclosed
US-20060135483-A1 Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases METABASIS THERAPEUTICS, INC. 2006-06-22 US disclosed
WO-2006017124-A2 OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES CENGENT THERAPEUTICS, INC. (US) 2006-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135483-A1 Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases PTPRO, PTPRG, PTPN1 PTPN1 3/4885PTPN2 24/4885PLG 3242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.